Sarepta Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Leadership transition is underway with a focus on strategic priorities for 2026, including ELEVIDYS stabilization, pipeline advancement, and financial strength. Strong financials, robust pipeline progress, and positive regulatory outlook support growth, with pivotal siRNA trials planned for next year.
-
The meeting approved all five proposals, including director elections, executive compensation, and new equity plans. Shareholders raised questions about board composition, CEO succession, and compensation, with the board emphasizing stability and ongoing performance improvements.
-
Q1 2026 saw stabilized operations, strong cash reserves, and positive operating profit, with ELEVIDYS and PMO franchises performing steadily. Promising siRNA pipeline data and expanded commercial initiatives support full-year guidance of $1.2–$1.4 billion.
-
Preliminary phase I/II data for SRP-1001 (FSHD) and SRP-1003 (DM1) show robust, dose-dependent muscle delivery, strong gene knockdown, and favorable safety profiles. Both programs plan to advance to phase III in 2027, with more MAD data expected later this year.
-
Revenue guidance for 2026 remains strong, with ELEVIDYS and PMO franchises supported by robust clinical data and ongoing sales force expansion. Key clinical milestones for DM1, FSHD, and nonambulant ELEVIDYS are on track, while pivotal trials and manufacturing scale-up are targeted for 2027.
-
Three-year data from the EMBARK Phase 3 trial show ELEVIDYS provides sustained and widening functional benefits in Duchenne muscular dystrophy, with a 70% reduction in disease progression and no new safety concerns. Early intervention is emphasized, and ongoing follow-up will further inform long-term outcomes.
-
Strong financial performance in 2025 sets the stage for growth in 2026, with Elevidys and PMOs driving revenue and a robust siRNA pipeline advancing. Enhanced safety measures, regulatory progress, and newborn screening initiatives are expected to expand market reach.
Fiscal Year 2025
-
Entered 2026 with strong financials, $2.2B 2025 revenue, and $954M cash. ELEVIDYS and PMO franchises remain stable, with new educational initiatives expected to drive 2026 revenue of $1.2–$1.4B. CEO to retire by end of 2026; robust pipeline and Japan launch support future growth.
-
Q3 revenues reached $399M, with strong PMO and ELEVIDYS sales despite shipment disruptions. ESSENCE trial for VYONDYS and AMONDYS showed clinical benefit trends but missed statistical significance, impacted by COVID-19. Financials improved via cost cuts, debt restructuring, and positive cash flow.
-
A fatal adverse event in a completed LGMD 2D trial was disclosed, with no impact on the known safety profile or regulatory status of Elevidys. Shipments for nonambulatory patients remain paused, and the FDA has not changed its position. Strategic focus has shifted to siRNA, with only SRP-9003 advancing.
-
A second non-ambulatory patient death from acute liver failure after Elevidys led to a pause in dosing and shipments for this group, pending protocol changes to add sirolimus for risk mitigation. Revenue guidance is suspended, and regulatory engagement is underway.
-
The meeting covered board and executive introductions, confirmed a quorum, and approved all five proposals, including director elections, executive compensation, equity plan amendments, and auditor ratification. A Q&A session followed for stakeholder engagement.
-
Q1 revenue grew 70% year-over-year, but guidance was lowered due to a safety event, longer therapy initiation times, and site capacity constraints. Regulatory progress continues, with key pipeline milestones and approvals expected through 2028. Financial strength supports ongoing operations and pipeline advancement.
-
Q1 2025 saw 70% net product revenue growth, led by ELEVIDYS, but guidance was revised to $2.3–$2.6B due to a safety event, administrative delays, and site capacity constraints. Cash remains strong, and a recovery is expected in the second half of the year.
-
Two-year EMBARK data show Elevidys provides significant, sustained functional and muscle health benefits in Duchenne patients, with early treatment yielding better outcomes and no new safety concerns. MRI and biomarker data reinforce the importance of early intervention. Results are expected to support payer and regulatory discussions.
-
Record revenue growth in 2024 was driven by Elevidys, the most successful gene therapy launch to date, with robust guidance for 2025 and a strong late-stage pipeline. Expansion efforts, new siRNA programs, and operational excellence position the company for sustained growth.
Fiscal Year 2024
-
ELEVIDYS drove record revenue growth in 2024, with net product revenue up 56% year-over-year and Q4 sales exceeding guidance. 2025 guidance projects 70% revenue growth, led by ELEVIDYS, and continued pipeline expansion through Arrowhead collaboration.
-
Q3 2024 saw 39% revenue growth year-over-year, driven by Elevidys and PMO franchises, with profitability achieved on both GAAP and non-GAAP bases. The company discontinued its PPMO program due to safety and regulatory concerns, while advancing late-stage LGMD and Elevidys programs. Guidance for 2025 and long-term growth remains strong.
-
ELEVIDYS achieved a broad label and strong launch, driving significant revenue growth and broad patient access. Manufacturing and supply are robust, with future scalability planned. Pipeline and business development efforts target further expansion, with a focus on rare and genetic diseases.
-
Q2 2024 saw a 51% year-over-year revenue increase to $362.9 million, driven by ELEVIDYS' expanded FDA approval and robust demand. 2025 revenue is guided at $2.9–$3.1 billion, with peak sales expected later in the decade and only modest PMO cannibalization anticipated.
-
ELEVIDYS received expanded FDA approval for Duchenne patients aged 4 and older, with strong clinical evidence and no near-term supply constraints. Pricing remains unchanged, supported by cost-effectiveness data, and broad site readiness ensures immediate access. Ongoing studies aim to further expand eligibility and confirm long-term benefits.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by shareholders. No additional proposals were introduced, and no questions were raised during the Q&A session.